AT-076
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(3R)-7-hydroxy-N-[(2S)-1-[4-(3-hydroxyphenyl)piperidin-1-yl]-3-methylbutan-2-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
|
|
| Identifiers | |
| PubChem | CID 91938095 |
| Chemical data | |
| Formula | C26H35N3O3 |
| Molar mass | 437.58 g·mol−1 |
| 3D model (Jmol) | Interactive image |
|
|
|
|
AT-076 is a so-called opioid "pan" antagonist and is the first reasonably balanced antagonist known of all four opioid receptor types.[1] It acts as a silent antagonist of all four of the opioid receptors, behaving as a competitive antagonist of the μ-opioid receptor (Ki = 1.67 nM) and δ-opioid receptor (Ki = 19.6 nM) and as a noncompetitive antagonist of the κ-opioid receptor (Ki = 1.14 nM) and nociceptin receptor (Ki = 1.75 nM).[1] AT-076 was derived from the selective κ-opioid receptor antagonist JDTic via removal of the 3,4-dimethyl group of the trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine antagonist scaffold, which increased affinity for the nociceptin receptor by 10-fold and for the μ- and δ-opioid receptors by 3-6-fold.[1]
See also[edit]
References[edit]
- ^ a b c Zaveri NT, Journigan VB, Polgar WE (2015). "Discovery of the First Small-Molecule Opioid Pan Antagonist with Nanomolar Affinity at Mu, Delta, Kappa, and Nociceptin Opioid Receptors". ACS Chem Neurosci. 6: 646–57. doi:10.1021/cn500367b. PMC 4401318
. PMID 25635572.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
